1. |
U. S. national library of medicine. What is precision medicine? Available from: https://ghr.nlm.nih.gov//primer/precisionmedicine/definition.
|
2. |
The white house. The precision medicine initiative. Available from: https://obamawhitehouse.archives.gov/precision-medicine.
|
3. |
吴思竹, 钱庆, 杨林. 中国, 美国, 英国精准医学计划比较研究. 中国医院管理, 2017, 37(9): 77-80.
|
4. |
唐金陵, 李立明. 关于循证医学, 精准医学和大数据研究的几点看法. 中华流行病学杂志, 2018, 39(1): 1-7.
|
5. |
阎小妍, 董冲亚, 姚晨. 大数据时代的循证医学研究. 中国循证医学杂志, 2017, 17(3): 249-254.
|
6. |
李佳圆. 中国乳腺癌危险因素研究现况及其风险预测模型研究展望. 中国循证医学杂志, 2020, 20(7): 745-748.
|
7. |
曾春燕, 邱仁宗. 个性化医学/精准医学的伦理考虑. 医学与哲学(A), 2018, 39(7): 92-95.
|
8. |
李磊, 王国豫. 精准的医学与不精准的后果. 中国医学伦理学, 2018, 31(9): 8-13.
|
9. |
陶应时, 王国豫. 精准医学伦理: 当代生命伦理研究的新领域. 自然辩证法通讯, 2019, 41(7): 93-99.
|
10. |
中华人民共和国卫生计生委办公厅. 孕妇外周血胎儿游离DNA产前筛查与诊断技术规范. Available from: http://www.nhc.gov.cn/fys/s3581/201611/0e6fe5bac1664ebda8bc28ad0ed68389.shtml.
|
11. |
中华人民共和国医政医管局. 肿瘤个体化治疗检测技术指南(试行). Available from: http://www.nhc.gov.cn/yzygj/s3593/201507/fca7d0216fed429cac797cdafa2ba466.shtml.
|
12. |
中华人民共和国医政医管局. 药物代谢酶和药物作用靶点基因检测技术指南(试行). Available from: http://www.nhc.gov.cn/yzygj/s3593/201507/fca7d0216fed429cac797cdafa2ba466.shtml.
|
13. |
基因谷. 又一城市实行免费无创产前基因检测. Available from: https://www.sohu.com/a/341140816_733985.
|
14. |
U. S. food and drug administration. Table of pharmacogenomic biomarkers in drug Labeling. Available from: https://www.fda.gov/drugs/science-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling.
|
15. |
Ashley EA. Towards precision medicine. Nat Rev Genet, 2016, 17(9): 507-522.
|
16. |
Ormond KE, Cho MK. Translating personalized medicine using new genetic technologies in clinical practice: the ethical issues. Per Med, 2014, 11(2): 211-222.
|
17. |
McGowan ML, Settersten RA, Juengst ET, et al. Integrating genomics into clinical oncology: ethical and social challenges from proponents of personalized medicine. Urol Oncol, 2014, 32(2): 187-192.
|
18. |
Buchanan A, Sachs A, Toler T, et al. NIPT: current utilization and implications for the future of prenatal genetic counseling. Prenat Diagn, 2014, 34(9): 850-857.
|
19. |
中国遗传学会遗传咨询分会. 分会简介. Available from: http://cbgc.org.cn/profile/introduce/.
|
20. |
Regier DA, Peacock SJ, Pataky R, et al. Societal preferences for the return of incidental findings from clinical genomic sequencing: a discrete-choice experiment. CMAJ, 2015, 187(6): E190-E197.
|
21. |
Shahmirzadi L, Chao EC, Palmaer E, et al. Patient decisions for disclosure of secondary findings among the first 200 individuals undergoing clinical diagnostic exome sequencing. Genet Med, 2014, 16(5): 395-399.
|
22. |
Schuol S, Schickhardt C, Wiemann S, et al. So rare we need to hunt for them: reframing the ethical debate on incidental findings. Genome Med, 2015, 7(1): 83.
|
23. |
Kohane IS, Masys DR, Altman RB. The incidentalome: a threat to genomic medicine. JAMA, 2006, 296(2): 212-215.
|
24. |
Green RC, Berg JS, Grody WW, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med, 2013, 15(7): 565-574.
|
25. |
Holtzman NA. ACMG recommendations on incidental findings are flawed scientifically and ethically. Genet Med, 2013, 15(9): 750-751.
|
26. |
Burke W, Antommaria AH, Bennett R, et al. Recommendations for returning genomic incidental findings? We need to talk! Genet Med, 2013, 15(11): 854-859.
|
27. |
ACMG Board of Directors. ACMG policy statement: updated recommendations regarding analysis and reporting of secondary findings in clinical genome-scale sequencing. Genet Med, 2015, 17(1): 68-69.
|
28. |
Chan SL, Samaranayake N, Ross CJ, et al. Genetic diversity of variants involved in drug response and metabolism in Sri Lankan populations: implications for clinical implementation of pharmacogenomics. Pharmacogenet Genomics, 2016, 26(1): 28-39.
|
29. |
Peng Q, Huang S, Chen X, et al. Validation of warfarin pharmacogenetic algorithms in 586 Han Chinese patients. Pharmacogenomics, 2015, 16(13): 1465-1474.
|
30. |
Johnson JA, Cavallari LH. Warfarin pharmacogenetics. Trends Cardiovasc Med, 2015, 25(1): 33-41.
|
31. |
Need AC, Goldstein DB. Next generation disparities in human genomics: concerns and remedies. Trends Genet, 2009, 25(11): 489-494.
|
32. |
Korngiebel DM, Thummel KE, Burke W. Implementing precision medicine: the ethical challenges. Trends Pharmacol Sci, 2017, 38(1): 8-14.
|
33. |
Aronson SJ, Rehm HL. Building the foundation for genomics in precision medicine. Nature, 2015, 526(7573): 336-342.
|
34. |
中华人民共和国科学技术部. 科技部关于发布国家重点研发计划精准医学研究等重点专项2016年度项目申报指南的通知. Available from: http://www.most.gov.cn/tztg/201603/t20160308_124542.htm.
|
35. |
王博, 刘芳, 张二春, 等. 国家基因库: 共有, 共为, 共享. 遗传, 2019, 41(8): 761-772.
|
36. |
薛江莉. 泰州队列生物样本库资源共享管理优化研究. 桂林: 广西师范大学, 2019.
|
37. |
Callier SL, Abudu R, Mehlman MJ, et al. Ethical, legal, and social implications of personalized genomic medicine research: current literature and suggestions for the future. Bioethics, 2016, 30(9): 698-705.
|
38. |
Helgesson G. In defense of broad consent. Camb Q Healthc Ethics, 2012, 21(1): 40-50.
|
39. |
Caulfield T. Biobanks and blanket consent: the proper place of the public good and public perception rationales. Kings Law J, 2007, 18(2): 209-226.
|
40. |
Grady C, Eckstein L, Berkman B, et al. Broad consent for research with biological samples: workshop conclusions. Am J Bioeth, 2015, 15(9): 34-42.
|
41. |
UK biobank. Consent form: UK biobank (version 20061124). Available from: https:/www.ukbiobank.ac.uk/wp-content/uploads/2011/06/Consent_form.pdf?phpMyAdmin=trmKQlYdjjnQIgJ%2CfAzikMhEnx6.
|
42. |
Elger B, Biller-Andorno N, Mauron A, et al. Ethical issues in governing biobanks: global perspectives. Farnham: Routledge, 2008.
|
43. |
Kaye J, Whitley EA, Lund D, et al. Dynamic consent: a patient interface for twenty-first century research networks. Eur J Hum Genet, 2015, 23(2): 141-146.
|
44. |
Ploug T, Holm S. Meta consent: a flexible and autonomous way of obtaining informed consent for secondary research. BMJ, 2015, 350: h2146.
|
45. |
Appelbaum PS, Parens E, Waldman CR, et al. Models of consent to return of incidental findings in genomic research. Hastings Cent Rep, 2014, 44(4): 22-32.
|
46. |
Weiner C. Anticipate and communicate: ethical management of incidental and secondary findings in the clinical, research, and direct-to-consumer contexts (December 2013 report of the Presidential Commission for the Study of Bioethical Issues). Am J Epidemiol, 2014, 180(6): 562-564.
|
47. |
Henderson GE, Juengst ET, King NM, et al. What research ethics should learn from genomics and society research: lessons from the ELSI Congress of 2011. J Law Med Ethics, 2012, 40(4): 1008-1024.
|
48. |
World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA, 2013, 310(20): 2191-2194.
|
49. |
Largent EA, Joffe S, Miller FG. Can research and care be ethically integrated? Hastings Cent Rep, 2011, 41(4): 37-46.
|
50. |
Bledsoe MJ, Clayton EW, McGuire AL, et al. Return of research results from genomic biobanks: cost matters. Genet Med, 2013, 15(2): 103-105.
|
51. |
Bledsoe MJ, Grizzle WE, Clark BJ, et al. Practical implementation issues and challenges for biobanks in the return of individual research results. Genet Med, 2012, 14(4): 478-483.
|
52. |
Kirschen MP, Jaworska A, Illes J. Subjects' expectations in neuroimaging research. J Magn Reson Imaging, 2006, 23(2): 205-209.
|
53. |
Miller FG, Joffe S. Evaluating the therapeutic misconception. Kennedy Inst Ethics J, 2006, 16(4): 353-366.
|
54. |
Homer N, Szelinger S, Redman M, et al. Resolving individuals contributing trace amounts of DNA to highly complex mixtures using high-density SNP genotyping microarrays. PLoS Genet, 2008, 4(8): e1000167.
|
55. |
McGuire AL, Hamilton JA, Lunstroth R, et al. DNA data sharing: research participants' perspectives. Genet Med, 2008, 10(1): 46-53.
|
56. |
Williams S, Scott J, Murphy J, et al. The genetic town hall: public opinion about research on genes, environment, and health. Available from: https://www.pewtrusts.org/en/research-and-analysis/reports/2009/01/30/the-genetic-town-hall-public-opinion-about-research-on-genes-environment-and-health.
|
57. |
Karlsen JR, Solbakk JH, Holm S. Ethical endgames: broad consent for narrow interests; open consent for closed minds. Camb Q Healthc Ethics, 2011, 20(4): 572-583.
|
58. |
Prainsack B, Buyx A. A solidarity-based approach to the governance of research biobanks. Med Law Rev, 2013, 21(1): 71-91.
|
59. |
转化医学网. 全面盘点|国内外消费级基因检测企业及产品. Available from: https://www.sohu.com/a/233602504_183834.
|
60. |
Niemiec E, Kalokairinou L, Howard HC. Current ethical and legal issues in health-related direct-to-consumer genetic testing. Per Med, 2017, 14(5): 433-445.
|
61. |
Almeling R, Gadarian SK. Public opinion on policy issues in genetics and genomics. Genet Med, 2014, 16(6): 491-494.
|
62. |
McGuire AL, Diaz CM, Wang T, et al. Social networkers' attitudes toward direct-to-consumer personal genome testing. Am J Bioeth, 2009, 9(6-7): 3-10.
|
63. |
Schaper M, Wöhlke S, Schicktanz S. "I would rather have it done by a doctor"-laypeople's perceptions of direct-to-consumer genetic testing (DTC GT) and its ethical implications. Med Health Care Philos, 2019, 22(1): 31-40.
|
64. |
Howard HC, Borry P. Is there a doctor in the house? The presence of physicians in the direct-to-consumer genetic testing context. J Community Genet, 2012, 3(2): 105-112.
|
65. |
Janssens AC, Gwinn M, Bradley LA, et al. A critical appraisal of the scientific basis of commercial genomic profiles used to assess health risks and personalize health interventions. Am J Hum Genet, 2008, 82(3): 593-599.
|
66. |
McGuire AL, Burke W. Health system implications of direct-to-consumer personal genome testing. Public Health Genomics, 2011, 14(1): 53-58.
|
67. |
Roberts JL, Pereira S, McGuire AL. Should you profit from your genome? Nat Biotechnol, 2017, 35(1): 18-20.
|